Atrys Health SA

Atrys Health operates with a capital structure that shows a debt-to-equity ratio of 1.7, indicating a relatively high leverage position. The company's liquidity is assessed as medium, with a current ratio of 0.81, suggesting that it may struggle to meet short-term obligations with its current assets. The company's valuation snapshot reveals a negative return on equity of -0.6605 and a negative return on assets of -0.203, indicating poor profitability relative to its equity and asset base. In terms of profitability, Atrys Health reported a net loss of EUR -100,296,000 and an operating loss of EUR -41,744,000 in the latest financial period. These figures suggest that the company is not currently generating sufficient revenue to cover its operating costs, which is a concern when compared to industry benchmarks for healthcare facilities and services. The company's gross profit of EUR 61,346,000 is a positive sign, but it is not enough to offset the operating and net losses. Atrys Health's revenue is primarily concentrated in Spain, with its diagnostic laboratories and translational research located in Barcelona and Granada, and offices in Madrid. The company's geographic exposure is limited, which could be a risk factor if the Spanish healthcare market experiences economic downturns or regulatory changes. The company's segments include Laboratory, Telemedicine, Radiotherapy, and Research and Development, but the financial data does not provide a breakdown of revenue by segment. The company's growth trajectory is uncertain, as it reported a net loss and negative operating cash flow in the latest period. The company's capital expenditure of EUR -12,517,000 indicates ongoing investment in its operations, but the negative free cash flow of EUR -40,928,000 suggests that the company is not generating enough cash to fund its operations and investments. The company's outlook for the current and next fiscal years is not provided, but the negative financial performance in the latest period is a concern. The risk assessment for Atrys Health indicates a medium liquidity risk and a low dilution risk. The company's key flags include a negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations. The company's dilution potential is low, but the negative net income and operating cash flow could lead to future dilution if the company needs to raise additional capital. The company's risk assessment does not provide a detailed breakdown of other risk factors, but the negative financial performance is a significant concern. Recent events for Atrys Health include analyst estimates that suggest a mean price target of EUR 4.83 and a median price target of EUR 5.00. The company has received a mean recommendation of 1.33, indicating a generally positive outlook from analysts. The company has received two strong-buy ratings and one buy rating, with no hold ratings, suggesting that analysts are optimistic about the company's future performance. However, the company's current financial performance does not support these positive ratings, and further analysis is needed to understand the basis for the analyst estimates.